Abstract: The present invention relates to polypeptides directed against or specifically binding to C—X—C Motif chemokine receptor 2 (CXCR2) and in particular to polypeptides capable of modulating signal transduction from CXCR2. The invention also relates to nucleic acids, vectors and host cells capable of expressing the polypeptides of the invention, pharmaceutical compositions comprising the polypeptides and uses of said polypeptides and compositions for treatment of diseases involving aberrant functioning of CXCR2.
Type:
Grant
Filed:
June 26, 2017
Date of Patent:
October 11, 2022
Assignee:
Ablynx N.V.
Inventors:
Zarin Brown, Michelle Bradley, Steven John Charlton, Gino Anselmus Van Heeke, Karen Cromie, Bruno Dombrecht, Soren Steffensen, Judith Baumeister, Marie-Paule Bouche, Carlo Boutton, Marie-Ange Buyse, Veerle Snoeck, Stephanie Staelens
Abstract: Interleukin-6 (IL-6) antagonists are provided that are specific for binding to site II of IL-6. Methods of using such inhibitors to treat IL-6 related diseases, e.g., disease of the eye such as diabetic macular edema are disclosed.
Type:
Grant
Filed:
January 26, 2018
Date of Patent:
October 4, 2022
Assignee:
Sesen Bio, Inc.
Inventors:
Michael March Schmidt, Thomas M. Barnes, David V. Erbe, Eric Steven Furfine, Alison Tisdale
Abstract: The disclosure provides anti-myostatin antibodies and methods of making and using the same. Nucleic acids encoding the anti-myostatin antibodies and host cells comprising the nucleic acids are also provided. The anti-myostatin antibodies have uses that include treating a muscle wasting disease, reducing body fat accumulation, and increasing mass and strength of muscle tissue. The disclosure also provides polypeptides containing a variant Fc region and methods of making and using the same. Nucleic acids encoding the polypeptides and host cells comprising the nucleic acids are also provided. The polypeptides have uses that include suppressing the activation of immune cells; treating an immunological inflammatory disease, autoimmune disease, or viral infection; and increasing muscle mass and strength or reducing body fat accumulation.
Abstract: Compositions and methods for the treatment of diseases, disorders, and/or conditions associated with the increased regulatory T lymphocyte cell function, comprising the administration of T-cell checkpoint inhibitors in combination with E-selectin inhibitors, C—X—C Motif Chemokine Receptor 4 (CXCR4) receptor inhibitors, and/or heterobifunctional inhibitors that comprise at least one E-selectin inhibitor linked to at least one CXCR4 receptor inhibitor, are disclosed.
Abstract: The present invention relates to a pharmaceutical composition for treating a cancer or an infection in a subject by administrating an amount of an interleukin 15 (IL-15) derivative conjugate so as to induce a proliferation of natural killer cells (NK cells) which is the same or higher than the one obtained with high dose of interleukin-2 (HDIL-2); eventually associated with a pharmaceutically acceptable carrier.
Abstract: The invention provides anti-myostatin antibodies and methods of using the same. In some embodiments, an isolated anti-myostatin antibody of the present invention binds to mature myostatin, and uptake of the antibody into cells is enhanced when complexed with the antigen. The invention also provides isolated nucleic acids encoding an anti-myostatin antibody of the present invention. The invention also provides host cells comprising a nucleic acid of the present invention. The invention also provides a method of producing an antibody comprising culturing a host cell of the present invention so that the antibody is produced. Anti-myostatin antibodies of the present invention may be for use as a medicament. Anti-myostatin antibodies of the present invention may be for use in treating a muscle wasting disease. Anti-myostatin antibodies of the present invention may be for use in increasing mass of muscle tissue.
Abstract: The present disclosure provides anti-nucleolin antibodies, methods of producing anti-nucleolin antibodies, and cells producing anti-nucleolin antibodies. Also provided are methods of using anti-nucleolin antibodies in treating malignant and non-malignant diseases.
Type:
Grant
Filed:
March 7, 2017
Date of Patent:
June 14, 2022
Assignee:
MUSC FOUNDATION FOR RESEARCH DEVELOPMENT
Inventors:
Daniel Fernandes, Laura Schwartz, Natalie Sutkowski, Brian Hoel, Semyon Rubinchik
Abstract: A method for diagnosing acute coronary syndrome (ACS) in a subject, the method comprising measuring plasma macrophage migration inhibitory factor (MIF) concentration in a sample from the subject, and diagnosing ACS when the subject plasma MIF concentration is greater than a reference plasma MIF concentration, wherein the sample is taken less than 4 hours after symptom onset. The invention also relates to a method for prognosing ACS in a subject, the method comprising measuring plasma MIF concentration in a sample from the subject, diagnosing ACS when the subject plasma MIF concentration is greater than a reference plasma MIF concentration, and prognosing the magnitude of ACS from the subject plasma MIF concentration. Also provided is a method of treating ACS in a subject, a device, a kit, and a cardiac biomarker related to the methods of diagnosing and prognosing ACS.
Type:
Grant
Filed:
February 12, 2014
Date of Patent:
June 14, 2022
Assignees:
ALFRED HEALTH, BAKER IDI HEART AND DIABETES INSTITUT HOLDINGS LTD.
Abstract: The invention provides for methods for treating a hair loss disorder in a subject by administering a Janus Kinase/Signal Transducers and Activators of Transcription inhibitor.
Type:
Grant
Filed:
March 12, 2019
Date of Patent:
April 12, 2022
Assignee:
THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK
Abstract: Described are pharmaceutical compositions comprising recombinant human chorionic gonadotropin (hCG) and follicle stimulating hormone (FSH), wherein the recombinant hCG in the composition comprises ?2,3- and ?2,6-sialylation and comprises mono-(1S), di-(2S), tri-(3S) and tetra-(4S) sialylated glycan structures. The recombinant hCG may be obtained by expression in a human cell line, such as the PER.C6 cell line, optionally wherein the cell line is modified using ?2,3-sialyltransferase.
Type:
Grant
Filed:
December 10, 2019
Date of Patent:
April 5, 2022
Assignee:
FERRING B.V.
Inventors:
Ian Cottingham, Daniel Plaksin, Richard White
Abstract: The present disclosure relates to methods, uses, medicaments, pharmaceutical formulations, dosage forms, and kits for inhibiting the progression of structural damage in psoriatic arthritis (PsA) patients using Interleukin-17 (IL-17) antagonists, e.g., IL-17 antibodies and antigen-binding fragments thereof, e.g., secukinumab.
Type:
Grant
Filed:
September 8, 2015
Date of Patent:
March 22, 2022
Assignee:
NOVARTIS AG
Inventors:
Shephard Mpofu, Hanno Richards, Gregory Ligozio
Abstract: The present invention provides antibodies and antigen-binding fragments (e.g., human antibodies) that bind specifically to human Interleukin-36 receptor (IL36R). Methods for treating or preventing diseases mediated by IL36R (e.g., skin or colon inflammatory conditions such as palmo-plantar pustular psoriasis, palmoplantar pustulosis, generalized pustular psoriasis, ulcerative colitis or IBD) using the antibodies and fragments are also provided along with methods of making the antibodies and fragments.
Type:
Grant
Filed:
July 16, 2019
Date of Patent:
March 8, 2022
Assignee:
Regeneron Pharmaceuticals, Inc.
Inventors:
Jeanette Fairhurst, Elena Garnova, William Olson, Sokol Haxhinasto
Abstract: Disclosed is an isolated monoclonal antibody against a human Transforming Growth Factor-? (TGF-?) Latency Associated Protein (LAP) degradate, the isolated monoclonal antibody being capable of recognizing an integrin binding site in the human TGF-? LAP degradate.
Type:
Grant
Filed:
July 17, 2020
Date of Patent:
March 1, 2022
Assignees:
RIKEN, THE JIKEI UNIVERSITY, SYSMEX CORPORATION
Abstract: The present invention provides a prophylactic or therapeutic agent for a kidney disease, comprising Apoptosis Inhibitor of Macrophage (AIM) or a partial peptide thereof, or a nucleic acid comprising a base sequence encoding the same, or a screening method for a prophylactic or therapeutic agent for a kidney disease, comprising using an animal obtained by subjecting a non-human mammal deficient in AIM expression to unilateral ureteral obstruction or transient kidney ischemia/reperfusion and the like.
Abstract: Disclosed herein are antibodies that specifically bind human erythroferrone and assay methods for detecting and/or measuring human erythroferrone, analogs of human erythroferrone, and fragments thereof. Specifically, the methods comprising using an antibody as a capture reagent and an antibody as a detection reagent for detecting or measuring a detectable label of the at least one detection reagent bound to the erythroferrone polypeptide that is bound to the capture reagent. Further disclosed are the sequences of antibodies.
Type:
Grant
Filed:
May 28, 2018
Date of Patent:
February 22, 2022
Assignee:
The Regents of the University of California
Inventors:
Tomas Ganz, Elizabeta Nemeth, Leon Kautz, Chun-Ling Jung
Abstract: The present invention provides novel humanized anti-human C—C chemokine receptor type 7 (CCR7) antibodies and compositions comprising such antibodies. The antibodies and compositions are useful in the treatment of a cancer of which the tumour cells express a CCR7 receptor, in the treatment of inflammatory conditions, conditions or complications arising from tissue or organ transplantations, and conditions or complications arising from or associated with fibrosis. The invention further provides nucleic acid molecules encoding the anti-CCR7 antibodies, cells expressing the anti-CCR7 antibodies and methods for producing the anti-CCR7 antibodies.
Type:
Grant
Filed:
March 10, 2020
Date of Patent:
February 22, 2022
Assignee:
PepMab B.V.
Inventors:
Jaap Willem Back, Ronald Boshuizen, Wouter Cornelis Puijk, Johan Turkstra, Klaus Heinrich Schwamborn
Abstract: The present disclosure relates to methods for generating blood protein profiles in red blood cell-enriched blood samples. The disclosed methods represent a new and improved laboratory technique for producing a protein profile from blood, increasing protein detection.
Type:
Grant
Filed:
October 6, 2016
Date of Patent:
February 8, 2022
Assignee:
SANGUI BIO PTY LTD.
Inventors:
Elisabeth Karsten, Ben Herbert, Alan Liddle, Cameron Hill
Abstract: Disclosed herein are novel methods and compositions for targeting drug delivery systems to specific cells. One aspect relates to a drug delivery system comprising an elastin-like peptide (ELP) component and a ligand selected from the group consisting of an polymeric immunoglobulin receptor binding site in the C?3 domain of dimeric human IgA (mIgA) and knob capable of either drug encapsulation or drug attachment. Further aspects relate to drug delivery systems comprising an elastin-like peptide (ELP) component and a ligand; wherein the ligand specifically binds to a receptor selected from the group consisting of coxsackievirus and adenovirus receptor (CAR) and polymeric immunoglobulin receptor (pIgR). Further aspects include the novel transcytosing properties of the elastin-like peptide and the ligand, knob. Also provided are methods and pharmaceutical compositions comprising the disclosed therapeutics.
Type:
Grant
Filed:
December 21, 2018
Date of Patent:
January 18, 2022
Assignee:
UNIVERSITY OF SOUTHERN CALIFORNIA
Inventors:
Sarah Hamm-Alvarez, John Andrew MacKay, Guoyong Sun, Pang-Yu Hsueh